Soleus Capital Management, L.P. Biomarin Pharmaceutical Inc Transaction History
Soleus Capital Management, L.P.
- $1.21 Billion
- Q1 2025
A detailed history of Soleus Capital Management, L.P. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Soleus Capital Management, L.P. holds 1,079,304 shares of BMRN stock, worth $61.4 Million. This represents 6.31% of its overall portfolio holdings.
Number of Shares
1,079,304
Previous 1,001,400
7.78%
Holding current value
$61.4 Million
Previous $65.8 Million
15.91%
% of portfolio
6.31%
Previous 4.58%
Shares
3 transactions
Others Institutions Holding BMRN
# of Institutions
668Shares Held
182MCall Options Held
1.22MPut Options Held
962K-
Black Rock Inc. New York, NY22.7MShares$1.29 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$1.08 Billion0.02% of portfolio
-
Primecap Management CO Pasadena, CA15.8MShares$897 Million0.71% of portfolio
-
Dodge & Cox San Francisco, CA15MShares$850 Million0.65% of portfolio
-
Viking Global Investors LP10.8MShares$614 Million2.55% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $10.6B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...